Australia markets closed

ImmunoPrecise Antibodies Ltd. (TQB.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
1.2000+0.0500 (+4.35%)
As of 08:11AM CEST. Market open.
Currency in EUR

Valuation measures4

Market cap (intra-day) 33.67M
Enterprise value 39.27M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)1.79
Price/book (mrq)0.89
Enterprise value/revenue 1.66
Enterprise value/EBITDA -4.09

Trading information

Stock price history

Beta (5Y monthly) 0.33
52-week change 3-49.56%
S&P500 52-week change 324.19%
52-week high 33.6200
52-week low 30.9200
50-day moving average 31.3676
200-day moving average 31.5131

Share statistics

Avg vol (3-month) 3182
Avg vol (10-day) 3275
Shares outstanding 526.32M
Implied shares outstanding 629.28M
Float 822.79M
% held by insiders 113.59%
% held by institutions 16.73%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:5
Last split date 323 Nov 2020

Financial highlights

Currency in CAD.

Fiscal year

Fiscal year ends 30 Apr 2023
Most-recent quarter (mrq)31 Jan 2024

Profitability

Profit margin -60.22%
Operating margin (ttm)-53.69%

Management effectiveness

Return on assets (ttm)-10.98%
Return on equity (ttm)-25.72%

Income statement

Revenue (ttm)23.68M
Revenue per share (ttm)0.94
Quarterly revenue growth (yoy)20.30%
Gross profit (ttm)N/A
EBITDA -12.21M
Net income avi to common (ttm)-14.26M
Diluted EPS (ttm)-0.3900
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)6.2M
Total cash per share (mrq)0.24
Total debt (mrq)14.39M
Total debt/equity (mrq)28.89%
Current ratio (mrq)1.66
Book value per share (mrq)1.89

Cash flow statement

Operating cash flow (ttm)-3.84M
Levered free cash flow (ttm)-858k